These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 1969059)
1. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Iggo R; Gatter K; Bartek J; Lane D; Harris AL Lancet; 1990 Mar; 335(8691):675-9. PubMed ID: 1969059 [TBL] [Abstract][Full Text] [Related]
2. p53: a frequent target for genetic abnormalities in lung cancer. Takahashi T; Nau MM; Chiba I; Birrer MJ; Rosenberg RK; Vinocour M; Levitt M; Pass H; Gazdar AF; Minna JD Science; 1989 Oct; 246(4929):491-4. PubMed ID: 2554494 [TBL] [Abstract][Full Text] [Related]
3. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. Takahashi T; D'Amico D; Chiba I; Buchhagen DL; Minna JD J Clin Invest; 1990 Jul; 86(1):363-9. PubMed ID: 2164047 [TBL] [Abstract][Full Text] [Related]
4. Mutations in the p53 gene occur in diverse human tumour types. Nigro JM; Baker SJ; Preisinger AC; Jessup JM; Hostetter R; Cleary K; Bigner SH; Davidson N; Baylin S; Devilee P Nature; 1989 Dec; 342(6250):705-8. PubMed ID: 2531845 [TBL] [Abstract][Full Text] [Related]
5. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410 [TBL] [Abstract][Full Text] [Related]
6. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413 [TBL] [Abstract][Full Text] [Related]
7. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Guinee DG; Travis WD; Trivers GE; De Benedetti VM; Cawley H; Welsh JA; Bennett WP; Jett J; Colby TV; Tazelaar H Carcinogenesis; 1995 May; 16(5):993-1002. PubMed ID: 7767998 [TBL] [Abstract][Full Text] [Related]
8. p53 alterations in plutonium-induced F344 rat lung tumors. Kelly G; Stegelmeier BL; Hahn FF Radiat Res; 1995 Jun; 142(3):263-9. PubMed ID: 7761575 [TBL] [Abstract][Full Text] [Related]
9. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Bartek J; Iggo R; Gannon J; Lane DP Oncogene; 1990 Jun; 5(6):893-9. PubMed ID: 1694291 [TBL] [Abstract][Full Text] [Related]
10. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M] J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499 [TBL] [Abstract][Full Text] [Related]
11. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer]. Zhang J; Zheng J; Fang W Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779 [TBL] [Abstract][Full Text] [Related]
12. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Menon AG; Anderson KM; Riccardi VM; Chung RY; Whaley JM; Yandell DW; Farmer GE; Freiman RN; Lee JK; Li FP Proc Natl Acad Sci U S A; 1990 Jul; 87(14):5435-9. PubMed ID: 2142531 [TBL] [Abstract][Full Text] [Related]
13. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160 [TBL] [Abstract][Full Text] [Related]
14. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Cheng J; Haas M Mol Cell Biol; 1990 Oct; 10(10):5502-9. PubMed ID: 2144611 [TBL] [Abstract][Full Text] [Related]
15. DNA distribution in non-small-cell lung carcinomas and its relationship to clinical behavior. Volm M; Mattern J; Sonka J; Vogt-Schaden M; Wayss K Cytometry; 1985 Jul; 6(4):348-56. PubMed ID: 2990835 [TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis]. Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638 [TBL] [Abstract][Full Text] [Related]
17. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922 [TBL] [Abstract][Full Text] [Related]
18. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937 [TBL] [Abstract][Full Text] [Related]
19. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
20. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Lohmann DR; Fesseler B; Pütz B; Reich U; Böhm J; Präuer H; Wünsch PH; Höfler H Cancer Res; 1993 Dec; 53(23):5797-801. PubMed ID: 8242638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]